TECHNOLOGY APPRAISAL IN ACTION

1
TECHNOLOGY APPRAISAL IN ACTION

• Mrs Karen Samuels
• Programme Manager

2

• WHO
• WHAT
• WHERE
• RELATED ORGANISATIONS
• CHALLENGES
• FUTURE

3
WMP MULTIDISCIPLINARYPARTNERSHIP

• 1. WMIC
• 2. WeMeReC
• 3. WCM Therapeutics and Toxicology Centre
• 4. YCC Wales
• (Core WMP)

4
ESTABLISHED 2002

• Appraised up to 8 High cost drugs per year
• Strategic advice
• Met 4 times per year

5
ORGANISATIONAL STRUCTURE
6
INITIAL PERIOD (2002-2006)

• One step process
• Public meeting
• WMP appraisal team
• One medical expert
• Patient perspective
• Two pharmaceutical company representatives

7
CHALLENGES

• One step
• Public nature
• Medical expert
• PIG submission
• Health Economic issues

8
CHALLENGES (continued)

• Small number of specialist medicines
• Dependent on pharmaceutical Industry submission
• Service links
• Need
• Commissioners (HCW)
• Public demand
  e.g.
  trastusumab

9
APRIL 2007

• Second phase, 32 appraisals per year
• 1. High cost
• 2. Cancer drugs
• 3. Cardiovascular drugs

10
MODIFIED PROCESS

• Met with SMC
• New sub group NMG

11
PROCESS

• In the pipeline
• MHRA licence (MA)
• Company launch in the UK
• Preliminary application (Form A)
• Detailed application (Form B)
• Patient Interest Groups

12
NMG ROLE AND MEMBERSHIP

• Expert clinical cost effectiveness advice to
  AWMSG
• Broad spectrum membership
• Lay representative
• ABPI representative
• Not in public

13
DATA CONSIDERED

• WMP assessment report (AS AR)
• Company response
• Companys detailed application (Form B)
• Advice from Medical Expert (s)
• Patient interest group submission

14
(No Transcript)
15
(No Transcript)
16
AWMSG ROLE AND MEMBERSHIP

• Consider strategic, societal, affordability
  aspects
• Broader strategic
• Senior NHS managers
• Senior Finance directors
• Lay representative
• ABPI representative

17
DATA CONSIDERED

• NMG preliminary appraisal report (PAR)
• Company response to the PAR
• Patient Interest Group submissions

18
(No Transcript)
19
HOW?

• In public
• Announced at the meeting
• Minister for Health and Social Services

20
RELATED ORGANISATIONS

• NICE/AWMSG/SMC
• ABPI
• CDG
• All-Wales Cardiac and Cancer networks
• Health Commission Wales

21
REQUEST FOR APPRAISAL OF CANCER DRUGS
Is drug/indication licensed?
No
Yes
Is drug being Appraised by NICE?
Refer to Cancer New Drugs Group for appraisal
No
Yes
Await NICE guidance
Refer to AWMSG for appraisal
22
ALL WALES CANCERDRUGS GROUP

• No backlog
• AWCDG to help prioritise
• Engaging network
• Oncologists
• Oncology pharmacists
• Horizon scanning

23

• England and Wales - NICE
• takes precedence
• Wales - AWMSG
• Local MTCs

24

• SCOTLAND
• SMC
• Streamlined process
• Similar paperwork
• Simultaneous submissions

25
ABPI

• Users Group
• Regular
• Input process

26
FUTURE

• Extend to all new medicines?
• Increased links with patient groups
• Further collaboration with NICE/SMC
• Review process after 2 cycles